{"id":104715,"date":"2026-02-10T01:14:06","date_gmt":"2026-02-10T01:14:06","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/epimab-biotherapeutics-announces-the-first-cta-filing-of-a-fit-ig-bispecific-antibody-by-its-license-partner-almirall\/"},"modified":"2026-02-10T01:14:06","modified_gmt":"2026-02-10T01:14:06","slug":"epimab-biotherapeutics-announces-the-first-cta-filing-of-a-fit-ig-bispecific-antibody-by-its-license-partner-almirall","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/epimab-biotherapeutics-announces-the-first-cta-filing-of-a-fit-ig-bispecific-antibody-by-its-license-partner-almirall\/","title":{"rendered":"EpimAb Biotherapeutics Announces the First CTA Filing of a FIT-IG\u00ae Bispecific Antibody by its License Partner Almirall"},"content":{"rendered":"<div id=\"main-body-container\" itemprop=\"articleBody\">\n<p align=\"justify\">SHANGHAI, Feb.  10, 2026  (GLOBE NEWSWIRE) &#8212; EpimAb Biotherapeutics, a clinical stage biopharmaceutical company specializing in the development of novel multispecific antibodies, today announced the achievement of a first CTA Filing by Almirall (www.almirall.com) under the license agreement between the companies completed in 2023.<\/p>\n<p align=\"justify\">Under the terms of the agreement, Almirall licensed EpimAb\u2019s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform technology to generate, develop and commercialize bispecific antibodies for up to three undisclosed target pairs. The first candidate to be advanced to clinical studies, under this license, will be a bispecific antibody targeting both IL-13 and OX-40L for the treatment of atopic dermatitis. Almirall expects to initiate its First-in-Human Phase 1 during the first half of 2026.<\/p>\n<p align=\"justify\">\u201cStarting with EpimAb\u2019s Technology, our partner Almirall successfully advanced its first bispecific candidate into clinical development, a defining moment for EpimAb as we are looking to apply our FIT-Ig technology in yet another disease area,\u201d said Dr. Chengbin Wu, CEO and founder of EpimAb. \u201cOur multiple partnerships on EpimAb\u2019s assets and platforms continue to deliver important preclinical and clinical milestones, demonstrating the power and versatility of our in-house derived technologies.\u201d<\/p>\n<p align=\"justify\">FIT-Ig, EpimAb\u2019s proprietary technology platform, generates bispecific antibodies solely utilizing the basic structural parts of monoclonal antibodies without adding any complex changes, and is patented in all major markets of the world. With multiple bispecific molecules advanced into the clinic using this technology, EpimAb has also demonstrated the potential of this novel platform to rapidly advance drug candidates from idea to development.<\/p>\n<p align=\"justify\">About EpimAb Biotherapeutics<\/p>\n<p align=\"justify\">EpimAb Biotherapeutics is a clinical-stage biopharmaceutical company specializing in the development of multi-specific antibodies. Utilizing a broad range of in-house research and technology capabilities, including the proprietary FIT-Ig (Fabs-In-Tandem Immunoglobulin) and MAT-Fab (Monovalent Asymmetric Tandem Fab) bispecific platform, EpimAb is generating and globally advancing a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer and autoimmune diseases patients.<\/p>\n<p align=\"justify\">For further information, please visit: www.epimab.com.<\/p>\n<p><strong>EpimAb Biotherapeutics Contacts<\/strong><\/p>\n<p>Investor Contact<br \/>Dr. David Gu, CFO<br \/>Direct: +86-21-61951011<br \/>IR@epimab.com<\/p>\n<p>BD Contact<br \/>Dr. Jason Tang, Senior BD Director<br \/>Direct: +86-21-61951014<br \/>partnering @epimab.com<\/p>\n<p>\n            <\/div>\n","protected":false},"excerpt":{"rendered":"<p>SHANGHAI, Feb. 10, 2026 (GLOBE NEWSWIRE) &#8212; EpimAb Biotherapeutics, a clinical stage biopharmaceutical company specializing in the development of novel multispecific antibodies, today announced the achievement of a first CTA Filing by Almirall (www.almirall.com) under the license agreement between the companies completed in 2023. Under the terms of the agreement, Almirall licensed EpimAb\u2019s proprietary Fabs-In-Tandem [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":104716,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml.globenewswire.com\/Resource\/Download\/fa1bd13e-e49a-4b2c-a742-85957a03ad87","fifu_image_alt":"","footnotes":""},"categories":[208],"tags":[],"class_list":["post-104715","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/104715","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/comments?post=104715"}],"version-history":[{"count":0,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/104715\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media\/104716"}],"wp:attachment":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media?parent=104715"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/categories?post=104715"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/tags?post=104715"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}